Last reviewed · How we verify

NCT05711108

Continuous Glucose Monitoring (CGM) in Long Term Care (LTC) Facilities

Completed Last updated 22 October 2025
What this trial tests

trial in Diabetes in 86 participants. Completed in 31 December 2024.

Timeline
19 January 2022
Primary endpoint
30 November 2024
31 December 2024

Quick facts

Lead sponsorJoslin Diabetes Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment86
Start date19 January 2022
Primary completion30 November 2024
Estimated completion31 December 2024
Sites1 location across United States

Conditions studied

Sponsor

Joslin Diabetes Center — full company profile →

Who can join

65 and older, any sex, with Diabetes or Hypoglycemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To prospectively determine the burden of hypoglycemia (minutes spent below 70 mg/dl per day, measured by continuous glucose monitor (CGM)) among residents of long term care facilities (LTC) with a diagnosis of type 1 or type 2 diabetes including key clinical subgroups (living in skilled nursing facility (SNF) or nursing home (NH), on different hypoglycemic medications). This aim will be achieved by recruiting 300 residents with diabetes in 4 LTC facilities. All participants will undergo masked CGM for 10 days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

Other Joslin Diabetes Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05711108.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing